EdiGene is focused on pioneering gene editing technologies aimed at developing transformative cell and gene therapies. The company has established two primary platforms: LEAPER and MAGIC. LEAPER is an innovative in vivo RNA base editing platform designed to address genetic disorders by enabling precise modifications to RNA, thereby offering potential treatments for conditions such as Duchenne Muscular Dystrophy and Usher Syndrome Type II. On the other hand, the MAGIC platform is dedicated to allogeneic cell therapies, particularly CAR-T therapies targeting difficult-to-treat cancers like relapsed/refractory non-Hodgkin B-cell lymphoma and various solid tumors.

EdiGene's commitment to advancing gene editing is underscored by its focus on original innovations and the development of differentiated products that can revolutionize disease treatment. The company is actively engaged in various stages of research and clinical trials, with a pipeline that includes both in vitro and in vivo therapies. By leveraging their proprietary technologies, EdiGene aims to create first-in-class therapies that address unmet medical needs, emphasizing a data-driven approach and collaboration to foster trust and respect within the scientific community.

China

EdiGene is a clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs. Anchored by its proprietary technologies of gene editing, bioinformatics, and high throughput genome-editing screening, EdiGene advances the pipeline on therapeutic platforms of LEAPER-based in vivo RNA base editing, ex vivo gene-editing hematopoietic stem cells, and ex vivo gene-editing T cells for allogeneic CAR-T.

EdiGene

Company Details